ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma

Classical Hodgkin lymphoma treatment is evolving rapidly with high response rates from antibody-drug conjugates targeting CD30 and immune checkpoint antibodies. However, most patients do not achieve a complete response, therefore development of novel therapies is warranted to improve patient outcome...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Principais autores: Batlevi, Connie Lee, Kasamon, Yvette, Bociek, R. Gregory, Lee, Peter, Gore, Lia, Copeland, Amanda, Sorensen, Rachel, Ordentlich, Peter, Cruickshank, Scott, Kunkel, Lori, Buglio, Daniela, Hernandez-Ilizaliturri, Francisco, Younes, Anas
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2016
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4967576/
https://ncbi.nlm.nih.gov/pubmed/27151994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2016.142406
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados